Hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment. Influence on LVH, proteinuria and metabolic parameters. The HANE Trial Research Group.
Kribben
A
A
Zentrum für Innere Medizin, Universitätsklinikum Essen, Berlin.
Anlauf
M
M
Distler
A
A
Gärtner
H
H
Holzgreve
H
H
Michaelis
J
J
Röcker
L
L
Schäfers
R
R
Philipp
U
U
Wellek
S
S
Philipp
T
T
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000419:Albuminuria; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001262:Atenolol / Q000627:therapeutic use; D001769:Blood / Q000378:metabolism*; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004232:Diuretics; D004311:Double-Blind Method; D004656:Enalapril / Q000627:therapeutic use; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D017379:Hypertrophy, Left Ventricular / Q000503:physiopathology*; D008875:Middle Aged; D009568:Nitrendipine / Q000627:therapeutic use; D016037:Single-Blind Method; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004232:Diuretics; D049993:Sodium Chloride Symporter Inhibitors; D006852:Hydrochlorothiazide; D001262:Atenolol; D004656:Enalapril; D009568:Nitrendipine